Library/For Long/Humanin

RUO · Research Use OnlyFor LongMitochondrial-encoded+1 more

Humanin

A 24-amino-acid peptide encoded by mitochondrial DNA. We read all 60 studies. The protocol is below.

Updated 03 May 2026Read 12 minEvidence ●○○○○Citations 60

+ Add to Stack⚖ Compare

⚖ Compare side-by-side ⎙ Print companion card

Free — puts Humanin on your decision board.

The Humanin Report · $19

Everything you need to start: dose, sourcing, safety, our verdict.

One purchase · yours forever

Built from 60 cited studies.

Status

Research-only

Class

For Long

Evidence

1/ 5●○○○○

Interventional human trials

$19 ↓

Animal studies

$19 ↓

Endogenous compound

$19 ↓

Read this if

you're already running MOTS-c and want the next mitochondrial-derived peptide
you have a parent slipping into MCI and you're reading every centenarian-biology paper you can find
you understand the supply chain is thin and you're okay with that
**what good looks like on the label — there are three different molecules sold as "humanin": native HN (24-aa, mild), S14G-HN / HNG (synthetic analog, ~1,000× more potent in cell assays; Hashimoto 2001 PMID 11371646), and HNGF6A (further-modified analog).** RUO vendors swap labels. If your bottle says "humanin" with no qualifier, assume native — and assume the studies you read used the analog, not what's in your vial.

Skip this if

**you have a personal or first-degree-family cancer history — this is the molecule to skip.** Humanin's anti-apoptotic mechanism is the concern: apoptosis is the body's primary defense against pre-cancerous cells, and a molecule that blocks apoptosis chronically could in theory protect tumor cells too. No human data either way — but with cancer history in the room, the mechanism alone is enough to walk
**you're on insulin, a sulfonylurea, or any hypoglycemic agent** — humanin enhances glucose-stimulated insulin secretion *and* increases insulin sensitivity (Muzumdar 2009 PMC 2709436); the additive hypoglycemia risk has no clinical-pharmacology data, just mechanism — don't stack without your endocrinologist
you want clean human RCTs — they're not there
you're looking for a first-line cognitive or metabolic intervention
you have a known mitochondrial disease and aren't being managed by a specialist

The 4 ways you can buy Humanin

No FDA-approved humanin exists.

Compounded 503A

✓

Off-label

$200–$400/mo where sold

Mid–high. Few compounders carry; zero human trials means clinical legitimacy is weak.

RUO (research-only)

✓

Sold 'for research only'

$80–$200/mo

The dominant supply; 24-residue peptide is moderately difficult to synthesize, identity-failures a…

Gray market

✓

Unregulated overseas import

Varies — not on user's vendor list

Available via overseas raws but humanin's research-only status means most gray vendors don't stock…

Click any lane for the full Sourcing breakdown. Prices and lane availability vary by molecule — this is the per-peptide snapshot, not a generic table.

First 90 days · Humanin

What we'd actually do

Weeks 1–2

Nothing perceptible. Longevity peptides are not 'feel something' molecules. If a vendor says you'll notice an effect this fast, they're selling you on placebo.

Weeks 4–8

Possibly subtle shifts in biomarkers (inflammation, sleep, recovery). Subjective changes in this window are usually placebo and confounded with whatever else you changed.

Week 12 — decide

Bloodwork or biomarker check. If the protocol can't be defended on a labeled change at 12 weeks, it can't be defended on hope.

Quit if

Any unusual symptoms — especially the cancer-mechanism flag for angiogenic peptides.
12 weeks of continuous use with no objective biomarker support to keep going.
Tolerance signal (the protocol needs escalating doses to feel the same).

Identity

What it is.

Humanin is a 24-amino-acid encoded inside the mitochondrial genome — like MOTS-c, it belongs to the small family of mitochondrial-derived peptides that signal back to the rest of the cell. It was discovered in 2001 by a Japanese group searching for protective factors against Alzheimer's-related neuron death.

The original finding: humanin protects neurons from amyloid-beta toxicity in cell culture. Since then, the literature has expanded into broader neuroprotection, cardioprotection, and metabolic effects, including improved insulin sensitivity in animal models.

Levels in human plasma drop with age. People with longevity-associated genetic variants (centenarian offspring) tend to have higher circulating humanin. That correlation is the engine behind the longevity- marketing.

There is no version. Sold strictly as a research chemical (RUO) in the US, often as a more stable analog called HNG (humanin-G).

TL;DR

TL;DR. 30-second version.

The compressed verdict — what Humanin actually is, what the human evidence shows, and the watch-for in three bullets. Locked.

Get the report · $19 ↓

Mechanism

Mechanism.

Mechanism · in the Humanin report

How the molecule actually works — receptor profile, downstream signaling, what to expect mechanistically.

Get the report · $19 ↓

Evidence

Evidence. What we actually know in humans.

Evidence · in the Humanin report

The trial breakdown — phase, n, primary endpoint, who funded, what hit, what didn't.

Get the report · $19 ↓

Human-Evidence Factbox

Interventional human trials

$19 ↓

Animal studies

$19 ↓

Endogenous compound

$19 ↓

Community dose (rodent-extrapolated)

$19 ↓

Half-life (estimated)

$19 ↓

Anti-apoptotic mechanism

$19 ↓

Isoform mislabel risk

$19 ↓

Insulin / hypoglycemic-agent stacking

$19 ↓

WADA status

$19 ↓

Long-term safety data

$19 ↓

Dose

Dose. The actual protocol.

Dose · in the Humanin report

The specific protocol — dose, titration schedule, cycle pattern, frequency, route.

We read 60 studies to write this report.

Get the report · $19 ↓

Sourcing

Sourcing. Where the cohort actually buys.

Sourcing · in the Humanin report

Sourcing breakdown — vendor methodology, red flags, our published test results, COA checklist.

We read 60 studies to write this report.

Get the report · $19 ↓

Safety

Safety. Side effects.

Safety · in the Humanin report

The watch-for list — contraindications, drug interactions, monitoring labs, when to stop.

Get the report · $19 ↓

Editorial Position

Editorial position.

Editorial Position · in the Humanin report

Our editorial position — explicit yes / no / depends, with the reasoning behind it.

Get the report · $19 ↓

Citations

Citations.

+Show all 60 citations

The Humanin Report · $19

Everything you need to start.

Dose, sourcing, safety, our verdict. One purchase. Yours forever.

Built from 60 cited studies.

Or get every report. All reports — $99 once · Pro — $29/mo.

Compare tiers →